

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Malte Peters *et al.*

Serial No.: 10/589,450

Filed: August 11, 2006

For: ANTI-EPCAM IMMUNOGLOBULINS

Group Art Unit: 1641

Examiner: Unknown

Atty. Dkt. No.: DEBE:069US

Confirmation No.: 5684

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

May 29, 2007

Date

Steven L. Highlander

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to

be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:069US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: May 29, 2007

Form PTO-1449 (modified)		Atty. Docket No.: <b>DEBE:069US</b>	Serial No.: <b>10/589,450</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: <b>Malte Peters <i>et al.</i></b>	
		Filing Date: <b>August 11, 2006</b>	Group: <b>1641</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Franz <i>et al.</i> , "Exacerbation of Wegener's Granulomatosis following Single Administration of Monoclonal Antibody 17-1A (Panorex) during Adjuvant Immunotherapy of Colon Cancer," <i>Onkologie</i> , 23:472-474, 2000.
	C2	Frodin <i>et al.</i> , "Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules," <i>Cancer Res.</i> , 50:4866-4871, 1990.
	C3	Herlyn <i>et al.</i> , "Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody," <i>Cancer Res.</i> , 40:717-721, 1980.
	C4	Koprowski <i>et al.</i> , "Colorectal carcinoma antigens detected by hybridoma antibodies," <i>Somatic Cell Genet.</i> , 5:957-971, 1979.
	C5	Lewis, "Technology evaluation: ING-1, XOMA," <i>Curr. Opin. Mol. Ther.</i> , 5:433-436, 2003.
	C6	Litvinov <i>et al.</i> , "Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins," <i>J. Cell Biol.</i> , 139:1337-1348, 1997.
	C7	McLaughlin <i>et al.</i> , "An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy," <i>Cancer Immunol. Immunother.</i> , 48:303-311, 1999.
	C8	Mellstedt <i>et al.</i> , "Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma," <i>Ann. NY Acad. Sci.</i> , 910:254-261, 2000.
	C9	Riethmuller <i>et al.</i> , "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial," <i>J. Clin. Oncol.</i> , 16:1788-1794, 1998.

25758390.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DEBE:069US	Serial No.: 10/589,450
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Malte Peters <i>et al.</i>	
		Filing Date: August 11, 2006	Group: 1641
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Riethmuller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group," <i>Lancet</i> , 343:1177-1183, 1994.
	C11	Spizzo <i>et al.</i> , "Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer," <i>Int. J. Cancer</i> , 98:883-888, 2002.

25758390.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.